Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3326-3333

  Imbuluzqueta, Edurne ^a   Gamazo, Carlos ^a   Lana, Hugo ^a   Campanero, Miguel Ángel ^b   Salas, David ^a   Gil, Ana Gloria ^a   Elizondo, Elisa ^c,d   Ventosa, Nora ^c,d   Veciana, Jaume ^c,d   Blanco Prieto, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIONIC SURFACTANT; DOXYCYCLINE; DRUG CARRIER; GENTAMICIN; GENTAMICIN BIS(2 ETHYLHEXYL) SULFOSUCCINATE SODIUM SALT; NANOPARTICLE; POLYGLACTIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRUCELLOSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN DISEASE; ZETA POTENTIAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BRUCELLA MELITENSIS; BRUCELLOSIS; CELL LINE; DRUG CARRIERS; FEMALE; GENTAMICINS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LACTIC ACID; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84879026380     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00378-13     Document Type: Article

References (47)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. 2006. The new global map of human brucellosis. Lancet Infect. Dis. 6:91-99. (Pubitemid 43138907)
2. Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O, Akdeniz H. 2010. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int. J. Infect. Dis. 14:e469-e78.
3. Zhong Z, Yu S, Wang X, Dong S, Xu J, Wang Y, Chen Z, Ren Z, Peng G. 2013. Human brucellosis in the People's Republic of China during 2005-2010. Int. J. Infect. Dis. 17:e289-e292.
4. Jelastopulu E, Merekoulias G, Alexopoulos EC. 2010. Underreporting of communicable diseases in the prefecture of Achaia, western Greece, 1999-2004: missed opportunities for early intervention. Euro Surveill. 15:19579. http://www.eurosurveillance.org/View/Article.aspx?ArticleId-19579.
5. Gruner E, Bernasconi E, Galeazzi RL, Buhl D, Heinzle R, Nadal D. 1994. Brucellosis: an occupational hazard for medical laboratory personnel. Report of five cases. Infection 22:33-36. (Pubitemid 24051841)
6. Yagupsky P, Baron EJ. 2005. Laboratory exposures to brucellae and implications for bioterrorism. Emerg. Infect. Dis. 11:1180-1185. (Pubitemid 41045323)
7. Robinson-Dunn B. 2002. The microbiology laboratory's role in response to bioterrorism. Arch. Pathol. Lab. Med. 126:291-294. (Pubitemid 34208118)
8. Gamazo C, Lecaroz MC, Prior S, Vitas AI, Campanero MA, Irache JM, Blanco-Prieto MJ. 2006. Chemical and biological factors in the control of Brucella and brucellosis. Curr. Drug Deliv. 3:359-365. (Pubitemid 44534047)
9. World Health Organization.1986. Joint FAO/WHO Expert Committee on Brucellosis. Sixth report. World Health Organ. Tech. Rep. Ser. 740:1-32.
10. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, Memish ZA, Roushan MR, Rubinstein E, Sipsas NV, Solera J, Young EJ, Pappas G. 2007. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 4:1872-1878. doi:10.1371/journal.pmed. 0040317.
11. Ersoy Y, Sonmez E, Tevfik MR, But AD. 2005. Comparison of three different combination therapies in the treatment of human brucellosis. Trop. Doct. 35:210-212. (Pubitemid 43105027)
12. Pappas G, Solera J, Akritidis N, Tsianos E. 2005. New approaches to the antibiotic treatment of brucellosis. Int. J. Antimicrob. Agents 26:101-105. (Pubitemid 41021960)
13. Armstead AL, Li B. 2011. Nanomedicine as an emerging approach against intracellular pathogens. Int. J. Nanomedicine 6:3281-3293.
14. Imbuluzqueta E, Gamazo C, Ariza J, Blanco-Prieto MJ. 2010. Drug delivery systems for potential treatment of intracellular bacterial infections. Front. Biosci. 15:397-417.
15. Lecaroz MC, Blanco-Prieto MJ, Campanero MA, Salman H, Gamazo C. 2007. Poly(D, L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob. Agents Chemother. 51:1185-1190. (Pubitemid 46586792)
16. Prior S, Gander B, Irache JM, Gamazo C. 2005. Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice. J. Antimicrob. Chemother. 55:1032-1036. (Pubitemid 40883195)
17. Imbuluzqueta E, Elizondo E, Gamazo C, Moreno-Calvo E, Veciana J, Ventosa N, Blanco-Prieto MJ. 2011. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections. Acta Biomater. 7:1599-1608.
18. Elizondo E, Sala S, Imbuluzqueta E, Gonzalez D, Blanco-Prieto MJ, Gamazo C, Ventosa N, Veciana J. 2011. High loading of gentamicin in bioadhesive PVM/MA nanostructured microparticles using compressed carbon-dioxide. Pharm. Res. 28:309-321.
19. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26:171-176. (Pubitemid 10086416)
20. Imbuluzqueta E, Lemaire S, Gamazo C, Elizondo E, Ventosa N, Veciana J, Van Bambeke F, Blanco-Prieto MJ. 2012. Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin. J. Antimicrob. Chemother. 67:2158-2164.
21. Gilbert DN. 2000. Aminoglycosides, p 307-336. In Mandell GL, Bennett JE, Dolin R (ed), Principles and practice of infectious disease. Churchill Livingstone, Philadelphia, PA.
22. Solera J, Martinez-Alfaro E, Espinosa A. 1997. Recognition and optimum treatment of brucellosis. Drugs 53:245-256. (Pubitemid 27073115)
23. Solera J, Medrano F, Rodriguez M, Geijo P, Paulino J. 1991. A comparative therapeutic and multicenter trial of rifampicin and doxycycline versus streptomycin and doxycycline in human brucellosis. Med. Clin. (Barc.) 96:649-653.
24. Ariza J, Gudiol F, Pallares R, Viladrich PF, Rufi G, Corredoira J, Miravitlles MR. 1992. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, doubleblind study. Ann. Intern. Med. 117:25-30.
25. Roushan MR, Amiri MJ, Janmohammadi N, Hadad MS, Javanian M, Baiani M, Bijani A. 2010. Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial. J. Antimicrob. Chemother. 65:1028-1035.
26. Solis Garcia del Pozo J, Solera J. 2012. Systematic review and metaanalysis of randomized clinical trials in the treatment of human brucellosis. PLoS One 7:e32090. doi:10.1371/journal.pone.0032090.
27. Lang R, Rubinstein E. 1992. Quinolones for the treatment of brucellosis. J. Antimicrob. Chemother. 29:357-360.
28. Lubani MM, Dudin KI, Sharda DC, Ndhar DS, Araj GF, Hafez HA, al-Saleh QA, Helin I, Salhi MM. 1989. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr. Infect. Dis. J. 8:75-78. (Pubitemid 19067079)
29. Montejo JM, Alberola I, Glez-Zarate P, Alvarez A, Alonso J, Canovas A, Aguirre C. 1993. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin. Infect. Dis. 16:671-676. (Pubitemid 23136567)
30. Celli J, de Chastellier C, Franchini DM, Pizarro-Cerda J, Moreno E, Gorvel JP. 2003. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J. Exp. Med. 198: 545-556. (Pubitemid 37040389)
31. Celli J, Gorvel JP. 2004. Organelle robbery: Brucella interactions with the endoplasmic reticulum. Curr. Opin. Microbiol. 7:93-97. (Pubitemid 38223960)
32. Lecaroz C, Blanco-Prieto MJ, Burrell MA, Gamazo C. 2006. Intracellular killing of Brucella melitensis in human macrophages with microsphere- encapsulated gentamicin. J. Antimicrob. Chemother. 58: 549-556. (Pubitemid 44288118)
33. Prior S, Gander B, Blarer N, Merkle HP, Subira ML, Irache JM, Gamazo C. 2002. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. 15:197-207. (Pubitemid 34155382)
34. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. 2005 Brucellosis. N. Engl. J. Med. 352:2325-2336.
35. Mingeot-Leclercq MP, Tulkens PM. 1999. Aminoglycosides: nephrotoxicity. Antimicrob. Agents Chemother. 43:1003-1012. (Pubitemid 29214718)
36. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. 1998. The pharmacodynamics of aminoglycosides. Clin. Infect. Dis. 27:23-27. (Pubitemid 28334413)
37. Turnidge J. 2003. Pharmacodynamics and dosing of aminoglycosides. Infect. Dis. Clin. North Am. 17:503-528. (Pubitemid 38029150)
38. Ali BH. 1995. Gentamicin nephrotoxicity in humans and animals: some recent research. Gen. Pharmacol. 26:1477-1487. (Pubitemid 26013171)
39. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. 1997. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin. Infect. Dis. 24:786-795. (Pubitemid 27193856)
40. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. 2004. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 114:e111-e8.
41. Nagai J, Takano M. 2004. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab. Pharmacokinet. 19:159-170.
42. Quiros Y, Vicente-Vicente L, Morales AI, Lopez-Novoa JM, Lopez-Hernandez FJ. 2011. An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. Toxicol. Sci. 119:245-256.
43. Kishore BK, Lambricht P, Ibrahim S, Laurent G, Tulkens PM, Maldague P. 1990. Inhibition of aminoglycoside-induced nephrotoxicity in rats by polyanionic peptides. Contrib. Nephrol. 83:191-201.
44. Lang R, Shasha B, Rubinstein E. 1993. Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. Antimicrob. Agents Chemother. 37:2333-2336. (Pubitemid 23324453)
45. Shasha B, Lang R, Rubinstein E. 1994. Efficacy of combinations of doxycycline and rifampicin in the therapy of experimental mouse brucellosis. J. Antimicrob. Chemother. 33:545-551. (Pubitemid 24110870)
46. Seleem MN, Jain N, Pothayee N, Ranjan A, Riffle JS, Sriranganathan N. 2009. Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline. FEMS Microbiol. Lett. 294:24-31.
47. Shasha B, Lang R, Rubinstein E. 1992. Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin. Antimicrob. Agents Chemother. 36:973-976.